Related Experiment Video
Updated: Jan 28, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Immunotherapy Toxicity
Charlene M Mantia1, Elizabeth I Buchbinder2
1Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.
Abstract:
The development of immunotherapy to target cancer has led to improved treatment of many types of malignancy. The immune checkpoint inhibitors are a class of medications that block cell signaling and allow the immune system to recognize and attack cancer cells. CTLA-4, PD-1, and PD-L1 inhibitors have been approved as treatment options in many different types of localized and advanced malignancies. Immune checkpoint inhibitors can be associated with unique side effects known as immune-related adverse events. Side effects most commonly occur in the skin, gastrointestinal tract, lung, and endocrine glands but can affect other organ systems as well.
Insights
Immunotherapy using immune checkpoint inhibitors like CTLA-4, PD-1, and PD-L1 blockers has advanced cancer treatment. These therapies can cause immune-related adverse events affecting various organs.
Area of Science:
- Oncology
- Immunology
Background:
- Cancer immunotherapy has significantly improved treatment outcomes for various malignancies.
- Immune checkpoint inhibitors (ICIs) represent a major advancement, enhancing the immune system's ability to target cancer cells.
Purpose of the Study:
- To provide an overview of immune checkpoint inhibitors in cancer treatment.
- To discuss the efficacy and potential side effects of these novel therapies.
Main Methods:
- Review of current literature on immune checkpoint inhibitors.
- Analysis of approved ICI targets including CTLA-4, PD-1, and PD-L1.
- Summarization of common and potential immune-related adverse events.
Main Results:
- Immune checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1 are approved for numerous localized and advanced cancers.
- These therapies work by blocking inhibitory signaling pathways, thereby unleashing anti-tumor immune responses.
Conclusions:
- Immune checkpoint inhibitors offer a powerful new modality in cancer therapy.
- Awareness and management of immune-related adverse events are crucial for patient safety and treatment success.
Related Concept Videos
Tumor Immunotherapy
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Frequency-dependent Selection
Predator-Prey Interactions
Responses to Salt Stress
Comparative Excretory Systems

